COMMUNIQUÉS West-GlobeNewswire

Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
18/03/2025
-- Prime Editing has potential to be best-in-class approach for AATD -- -- Previously undisclosed program now emerging from within liver platform; leverages proprietary, universal liver LNP -- -- High levels of editing [...]
Rhythm Pharmaceuticals and Raymond A. Wood Foundation Announce Research Collaboration
18/03/2025
New registry study to focus on impact of fatigue in people with craniopharyngioma BOSTON, March 18, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical [...]
Bio-Path Holdings Announces Pre-Clinical Results Signaling Increased Potential for BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients
18/03/2025
Recent Pre-Clinical Studies Showed BP1001-A Attenuated Fatty Acid-Induced Insulin Resistance and Restored Insulin Sensitivity in Muscle Progenitor and Skeletal Muscle Fiber Cell Models HOUSTON, March 18, 2025 (GLOBE [...]
ANI Pharmaceuticals Announces Buyout of Royalty Obligation for ILUVIEN® and YUTIQ®
18/03/2025
BAUDETTE, Minn., March 18, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that it has completed the buyout of its 3.125% perpetual royalty obligation to SWK [...]
Eton Pharmaceuticals Reports Fourth Quarter 2024 Financial Results
18/03/2025
Management to Hold Investor Day Conference Call Today at 10:00am ET Reported record product revenue of $11.6 million in Q4 2024, an increase of 59% over Q4 2023, representing the 16 th straight quarter of sequential [...]
Arbor Biotechnologies Announces $73.9 Million Series C Financing to Advance Novel Gene Editing Therapeutics
18/03/2025
Series C led by ARCH Venture Partners and TCGX with significant participation from existing and new investors Financing extends Arbor’s cash runway into 2027 and supports the clinical development of lead program ABO-101 [...]
EAACI Congress 2025 - Breaking Boundaries in Allergy, Asthma, and Clinical Immunology: Integrating Planetary Health for a Sustainable Future
18/03/2025
ZURICH, March 18, 2025 (GLOBE NEWSWIRE) -- The European Academy of Allergy and Clinical Immunology (EAACI) proudly presents the EAACI Congress 2025, set to take place June 13-16 in Glasgow, United Kingdom. This year’s [...]
Congrès 2025 de l’EAACI - Repousser les limites dans les domaines de l’allergie, de l’asthme et de l’immunologie clinique : intégrer la santé planétaire pour un avenir durable
18/03/2025
ZURICH, 18 mars 2025 (GLOBE NEWSWIRE) -- L’European Academy of Allergy and Clinical Immunology (EAACI) est fière d’annoncer la tenue du congrès 2025 de l’EAACI qui se tiendra au Royaume-Uni du 13 au 16 juin, dans la [...]
EnteroBiotix Announces Positive Topline Phase 2a Results with EBX-102-02, a Potential First-in-Class Treatment for Irritable Bowel Syndrome (IBS)
18/03/2025
EnteroBiotix Announces Positive Topline Phase 2a Results with EBX-102-02, a Potential First-in-Class Treatment for Irritable Bowel Syndrome (IBS) EBX-102-02 demonstrated clinically meaningful superiority over placebo in [...]
Tecan publishes agenda for the Annual General Meeting 2025
18/03/2025
Tecan publishes agenda for the Annual General Meeting 2025 Board of Directors will propose the re-election of seven current members Karen Huebscher will not be standing for re-election Myra Eskes, Christa Kreuzburg and [...]
Press Release Biocartis NV: Biocartis Announces Multiple Abstracts Demonstrating the Impact of Idylla™ in Oncology Diagnostics to be Presented at USCAP 2025 Annual Meeting
18/03/2025
PRESS RELEASE 18/03/2025, 07:00 CET Biocartis Announces Multiple Abstracts Demonstrating the Impact of Idylla™ in Oncology Diagnostics to be Presented at USCAP 2025 Annual Meeting Mechelen, Belgium, 18 March 2025 – [...]
Press release: Sequana Medical announces 2024 Full Year Results and 2025 Outlook
18/03/2025
Sequana Medical announces 2024 Full Year Results and 2025 Outlook alfapump® – US FDA approval of alfapump® for the treatment of recurrent or refractory ascites due to liver cirrhosis; US commercial launch planned for [...]
Press release: Sequana Medical Obtains Convertible Financing of EUR 4.0 Million from Major Shareholders and Committed Share Subscription Facility of up to EUR 60 Million from GEM
18/03/2025
Sequana Medical Obtains Convertible Financing of EUR 4.0 Million from Major Shareholders and Committed Share Subscription Facility of up to EUR 60 Million from GEM Continued support from major shareholders – new EUR 4.0 [...]
Illuccix® Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America
17/03/2025
MELBOURNE, Australia and PORTO ALEGRE, Brazil, March 18, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the Brazilian Health Regulatory Agency ( [...]
MEDIROM Healthcare Technologies Inc. Announces New JPY350 Million (Approximately $2.4 Million*) Unsecured Loan Financing
17/03/2025
TOKYO, March 17, 2025 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (Nasdaq CM: MRM), a holistic healthcare company based in Japan (the “Company” or “MEDIROM”), today announced that it has obtained a new [...]
Precipio Announces Q4 and year-end 2024 Shareholder Update Call
17/03/2025
Conference Call to be held on March 31st, 2025 at 5:00 PM EST NEW HAVEN, Conn., March 17, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , will be hosting its Q4 and year end [...]
XOMA Royalty Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Business Achievements
17/03/2025
Doubled the royalty and milestone portfolio to over 120 royalty assets with significant milestone potential through five transactions in 2024 Completed two whole company acquisitions to unlock shareholder value Day One’ [...]
Enzo Biochem Reports Second Quarter Fiscal Year 2025 Results
17/03/2025
FARMINGDALE, N.Y., March 17, 2025 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the fiscal second quarter ended January 31, 2025, with sequential [...]
NANOBIOTIX Strengthens Financial Position Through Amendment of Global Licensing Agreement for JNJ-1900 (NBTXR3) and Extends Cash Visibility to Mid-2026
17/03/2025
Conference call and webcast scheduled for March 18, 2025, at 8:30 A.M. EDT / 1:30 P.M. CET PARIS and CAMBRIDGE, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), [...]

Pages